Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex Holding Company, has secured a $20 million private placement to fund the second Phase 3 trial of SP-102 (SEMDEXA), a dexamethasone sodium phosphate viscous gel for lumbosacral radicular pain (LRP)/sciatica. The investment comes as Semnur prepares for its merger with Denali Capital Acquisition Corp, expected to close in September 2025. This cash infusion is crucial for advancing SEMDEXA through late-stage development and positions the company for a stronger market entry upon successful trial completion.
The timing of this funding, alongside the upcoming merger, suggests a strategic effort to bolster Semnur’s financial position and highlight the potential of SEMDEXA to investors. The proceeds will specifically support the second Phase 3 trial, a critical step towards regulatory approval and eventual commercialization. This targeted investment underscores the investor’s confidence in SEMDEXA’s prospects in the LRP/sciatica treatment market.
This development coincides with a significant leadership transition at Scilex. Jaisim Shah has stepped down as CEO and President of Scilex to focus solely on his role as CEO and President of Semnur. This shift allows Shah to dedicate his full attention to navigating Semnur through the complexities of the merger, the ongoing Phase 3 trial, and the anticipated public listing. Scilex Chairman Henry Ji, Ph.D., has assumed the CEO and President roles at Scilex. This restructuring appears designed to ensure dedicated leadership for both entities during this critical period.
The private placement and leadership change impact several stakeholders. For Semnur, the influx of capital de-risks the SEMDEXA development program, potentially accelerating its path to market. For Scilex, the leadership transition ensures continued focus on its existing commercial portfolio. For investors, this combination of events signals a strategic commitment to maximizing the value of both companies, separately and in conjunction. This move also underscores the increasing investment interest in non-opioid pain management solutions, a field gaining traction amid the ongoing opioid crisis.
The success of SEMDEXA’s second Phase 3 trial remains the linchpin for Semnur’s future. The trial results will not only determine the drug’s regulatory fate but also heavily influence the combined company’s valuation post-merger. Investors will be closely watching for trial data readouts, FDA feedback, and ultimately, the drug’s market access strategy. The ability of the new leadership teams at both Scilex and Semnur to navigate the post-merger integration while effectively advancing their respective pipelines will also be a key area of observation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
